Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Burning Rock Biotech (BNR) FCF Margin (2019 - 2025)

Burning Rock Biotech has reported FCF Margin over the past 7 years, most recently at 18.23% for Q4 2025.

  • For Q4 2025, FCF Margin rose 311.0% year-over-year to 18.23%; the TTM value through Dec 2025 reached 9.3%, up 3259.0%, while the annual FY2025 figure was 6.15%, 1279.0% up from the prior year.
  • FCF Margin for Q4 2025 was 18.23% at Burning Rock Biotech, up from 12.39% in the prior quarter.
  • Over five years, FCF Margin peaked at 18.23% in Q4 2025 and troughed at 189.57% in Q3 2023.
  • A 5-year average of 62.06% and a median of 68.13% in 2024 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: tumbled -15056bps in 2021 and later skyrocketed 10304bps in 2024.
  • Year by year, FCF Margin stood at 76.24% in 2021, then surged by 39bps to 46.16% in 2022, then skyrocketed by 71bps to 13.23% in 2023, then soared by 214bps to 15.12% in 2024, then rose by 21bps to 18.23% in 2025.
  • Business Quant data shows FCF Margin for BNR at 18.23% in Q4 2025, 12.39% in Q3 2025, and 45.25% in Q2 2025.